No Data
Chengdu Kanghua Biological Products Co., Ltd.'s (SZSE:300841) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Chengdu Kanghua Biological Products (300841.SZ): the company's production capacity utilization rate has been at a high level in recent years.
On July 22nd, Gelonghui reported that Chengdu Kanghua Biological Products (SZ:300841) stated on the investor platform that the company's production capacity utilization rate has remained high in recent years. The yearly demand for human rabies vaccine is huge, and the proportion of human diploid cell rabies vaccine in the rabies vaccine market is relatively small. Chengdu Kanghua differentiates itself by using human diploid cells as the substrate to culture rabies virus and has a large supplementary space for other cell substrate rabies vaccines. The company's freeze-dried human rabies vaccine (human diploid cells) is highly safe, immunogenic, and does not contain residual DNA or animal-source cell proteins.
Chengdu Kanghua Biological Products (300841.SZ): The technology related to 500L large-scale bioreactors has not yet been industrialized.
On July 22nd, Gelunhui reported that Chengdu Kanghua Biological Products (300841.SZ) stated on the investor interaction platform that the company's production of lyophilized human rabies vaccine (human diploid cell) is currently based on 100L bioreactor large-scale cultivation, amplification of human diploid cells technology and product platform, while 500L large-scale bioreactor related technology has not yet been industrialized.
Chengdu Kanghua Biological Products (300841.SZ) has spent 144 million yuan to buy back 2% of its shares.
Chengdu Kanghua Biological Products (300841.SZ) announced that as of July 3, 2024, the company has repurchased shares through a share buyback program...
Chengdu Kanghua Biological Products (300841.SZ) has repurchased 1.57% of its shares, with a total expenditure of 114 million yuan.
Chengdu Kanghua Biological Products (300841.SZ) announced that as of June 30, 2024, the company has repurchased a cumulative total of 2.1176 million shares, accounting for 1.57% of the company's current total share capital, with a total transaction amount of 114 million yuan (excluding transaction costs).
Here's Why Chengdu Kanghua Biological Products (SZSE:300841) Can Manage Its Debt Responsibly
Is Weakness In Chengdu Kanghua Biological Products Co., Ltd. (SZSE:300841) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?No Data
